Founded in 2010, BioLinq operates in medical devices / biotech. The latest valuation stands at $400M (post-money). No public ticker exists for the company.
One company valuation: $400M (post-money), dated Apr 2025.
Biolinq is a health technology company founded in 2010 and headquartered in the United States that develops needle-free biosensors for metabolic health. Its Biolinq Shine sensor measures glucose without a hypodermic needle, combining glucose, activity, and sleep data in one wearable device paired with a mobile app.
The Biolinq Shine device received FDA de novo clearance in 2025 as the first fully autonomous, needle-free glucose sensor, aimed at people with diabetes who are not on insulin.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds BioLinq.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. BioLinq availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — BioLinq included.
The routes section explains what is realistically available for a company at this stage.
No. BioLinq is a private company; its shares do not trade on a public exchange.
The last valuation is $400M (post-money, Apr 2025).
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
